Literature DB >> 21270761

Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy.

Stine E Nielsen1, Steen Andersen, Dietmar Zdunek, Georg Hess, Hans-Henrik Parving, Peter Rossing.   

Abstract

Recent studies have shown that both glomerular and tubulointerstitial damage are important factors in the pathophysiology and progression of diabetic nephropathy. To examine whether markers of tubular damage are useful in monitoring the progression of disease, we measured urinary levels of neutrophil gelatinase-associated lipocalin (NGAL), liver-fatty acid-binding protein (LFABP), and kidney injury molecule-1 (KIM-1) in a 3-year intervention study of 63 type 1 diabetic patients with kidney disease. The baseline mean glomerular filtration rate (GFR) was 87 ml/min per 1.73 m(2) and urinary albumin excretion 1141 mg/24 h. Patients with the highest compared with the lowest quartile of urinary NGAL at baseline had higher urinary KIM-1 levels and a significant decrease in their GFR each year. Using linear regression analysis, we found that elevated urinary NGAL and KIM-1 concentrations were associated with a faster decline in GFR, but not after adjustment for known promoters of progression. Urinary LFABP was not related to decline in GFR. Losartan treatment (100 mg/day) reduced urinary KIM-1 by 43% over a 12-month period. Thus, urine biomarker measurements in patients with type 1 diabetic nephropathy did not provide additional prognostic information to that of known progression promoters.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21270761     DOI: 10.1038/ki.2010.554

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  41 in total

1.  Association of urinary KIM-1, L-FABP, NAG and NGAL with incident end-stage renal disease and mortality in American Indians with type 2 diabetes mellitus.

Authors:  Gudeta D Fufaa; E Jennifer Weil; Robert G Nelson; Robert L Hanson; Joseph V Bonventre; Venkata Sabbisetti; Sushrut S Waikar; Theodore E Mifflin; Xiaoming Zhang; Dawei Xie; Chi-Yuan Hsu; Harold I Feldman; Josef Coresh; Ramachandran S Vasan; Paul L Kimmel; Kathleen D Liu
Journal:  Diabetologia       Date:  2014-10-15       Impact factor: 10.122

Review 2.  Proteinuria should be used as a surrogate in CKD.

Authors:  Paolo Cravedi; Piero Ruggenenti; Giuseppe Remuzzi
Journal:  Nat Rev Nephrol       Date:  2012-03-06       Impact factor: 28.314

3.  Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.

Authors:  William Brian Reeves; Bishal B Rawal; Emaad M Abdel-Rahman; Alaa S Awad
Journal:  Open J Nephrol       Date:  2012-06-25

4.  A novel urinary biomarker protein panel to identify children with ureteropelvic junction obstruction - A pilot study.

Authors:  Charan Kumar V Devarakonda; Emily R Shearier; Chaoran Hu; James Grady; Jeremy L Balsbaugh; John H Makari; Fernando A Ferrer; Linda H Shapiro
Journal:  J Pediatr Urol       Date:  2020-06-11       Impact factor: 1.830

Review 5.  Prevalence and Management of Diabetic Nephropathy in Western Countries.

Authors:  Bancha Satirapoj; Sharon G Adler
Journal:  Kidney Dis (Basel)       Date:  2015-05-01

6.  Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-β-d-Glucosaminidase, and Urinary β2-Microglobulin in Patients with Type 2 Diabetes and Biopsy-Proven Diabetic Nephropathy.

Authors:  Koki Mise; Junichi Hoshino; Toshiharu Ueno; Ryo Hazue; Jumpei Hasegawa; Akinari Sekine; Keiichi Sumida; Rikako Hiramatsu; Eiko Hasegawa; Masayuki Yamanouchi; Noriko Hayami; Tatsuya Suwabe; Naoki Sawa; Takeshi Fujii; Shigeko Hara; Kenichi Ohashi; Kenmei Takaichi; Yoshifumi Ubara
Journal:  Clin J Am Soc Nephrol       Date:  2016-01-22       Impact factor: 8.237

Review 7.  Diabetic Nephropathy: New Risk Factors and Improvements in Diagnosis.

Authors:  Konstantinos Tziomalos; Vasilios G Athyros
Journal:  Rev Diabet Stud       Date:  2015-08-10

8.  Urine Injury Biomarkers and Risk of Adverse Outcomes in Recipients of Prevalent Kidney Transplants: The Folic Acid for Vascular Outcome Reduction in Transplantation Trial.

Authors:  Nisha Bansal; Myra A Carpenter; Daniel E Weiner; Andrew S Levey; Marc Pfeffer; John W Kusek; Jianwen Cai; Lawrence G Hunsicker; Meyeon Park; Michael Bennett; Kathleen D Liu; Chi-Yuan Hsu
Journal:  J Am Soc Nephrol       Date:  2015-11-04       Impact factor: 10.121

Review 9.  The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease.

Authors:  Tomás P Griffin; William Patrick Martin; Nahidul Islam; Timothy O'Brien; Matthew D Griffin
Journal:  Curr Diab Rep       Date:  2016-05       Impact factor: 4.810

Review 10.  Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy.

Authors:  Gianfranco Tramonti; Yashpal S Kanwar
Journal:  Endocrine       Date:  2012-10-20       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.